RxDoctor Payments Data

Himanshu Parikh, MD

Family Medicine · Kingston, NYNPI 1992296297

Payments from drug & device makers

$836in general payments, 2019–2025

Across 38 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$197
  • AbbVie$156
  • Pfizer$147
  • Novo Nordisk$49
  • Inspire Medical Systems, Inc.$48
  • Bayer$35
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$836 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$14,249
Medicare patients
73
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$21,490
EliquisApixaban17$10,332
FarxigaDapagliflozin Propanediol16$10,282
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,261
SymbicortBudesonide/Formoterol Fumarate19$4,420
Albuterol Sulfate HfaAlbuterol Sulfate55$1,250
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$778
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm13$586
Tolterodine Tartrate ErTolterodine Tartrate12$566
Gabapentin61$552
Duloxetine Hcl29$342
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide27$321
Metformin Hcl ErMetformin Hcl19$274
Torsemide12$267
Metoprolol Succinate34$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$21,49023 claims
AstraZenecaFarxiga, Symbicort$197$14,70235 claims
PfizerEliquis$147$10,33217 claims
GSKTrelegy Ellipta$18$7,26111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →